Promising new drug combo aims to wipe out leukemia cells more effectively
NCT ID NCT07228273
First seen Nov 15, 2025 · Last updated May 11, 2026 · Updated 25 times
Summary
This study tests whether adding venetoclax to a standard chemotherapy regimen (FLAG IDA) can better eliminate leukemia cells in people newly diagnosed with acute myeloid leukemia (AML). About 102 adults aged 18 to 65 will be randomly assigned to receive either the new combination or standard treatment. The goal is to see if the new approach leads to deeper remissions with no detectable cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.